Glucagon Antikörper (N-Term)
-
- Target Alle Glucagon (GCG) Antikörper anzeigen
- Glucagon (GCG)
-
Bindungsspezifität
- AA 53-81, N-Term
-
Reaktivität
- Human, Ratte, Maus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser Glucagon Antikörper ist unkonjugiert
-
Applikation
- Immunohistochemistry (IHC), Immunofluorescence (IF)
- Verwendungszweck
- Anti-GLP1/GCG Antibody
- Sequenz
- HSQGTFTSDY SKYLDSRRAQ DFVQWLMNT
- Kreuzreaktivität (Details)
- No cross-reactivity with other proteins
- Produktmerkmale
- Anti-GLP1/GCG Antibody Picoband® (ABIN3042419). Tested in IF, IHC applications. This antibody reacts with Human, Mouse, Rat.
- Aufreinigung
- Immunogen affinity purified.
- Immunogen
- A synthetic peptide corresponding to a sequence at the N-terminus of human GLP1, identical to the related mouse and rat sequences.
- Isotyp
- IgG
- Top Product
- Discover our top product GCG Primärantikörper
-
-
- Applikationshinweise
-
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL, Human, Mouse, Rat
Immunofluorescence, 2 μg/mL, Rat
1. Arora S, Galich P (Mar 2009). "Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction". Cjem 11 (2): 169-71. 2. Holz, G. G., IV, Kuhtreiber, W. M., Habener, J. F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 361: 362-365, 1993. 3. Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, Lacy WW, Crofford OB, Liddle GW (Jan 1974). "Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men" (PDF). The Journal of Clinical Investigation 53 (1): 190-7. - Kommentare
-
Antibody can be supported by ABIN921231 in IHC(P).
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
- Konzentration
- 500 μg/mL
- Buffer
- Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Avoid repeated freezing and thawing.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
-
Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
-
-
Chronic oscillating glucose challenges disarrange innate immune homeostasis to potentiate the variation of neutrophil-lymphocyte ratio in rats with or without hidden diabetes mellitus." in: Diabetes, metabolic syndrome and obesity : targets and therapy, Vol. 11, pp. 277-288, (2018) (PubMed).
: "Low dose doxycycline decreases systemic inflammation and improves glycemic control, lipid profiles, and islet morphology and function in db/db mice." in: Scientific reports, Vol. 7, Issue 1, pp. 14707, (2017) (PubMed).
: "Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats." in: BioMed research international, Vol. 2013, pp. 526367, (2013) (PubMed).
: "Intra-arterial targeted islet-specific expression of Sirt1 protects ? cells from streptozotocin-induced apoptosis in mice." in: Molecular therapy : the journal of the American Society of Gene Therapy, Vol. 19, Issue 1, pp. 60-6, (2011) (PubMed).
: "Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer." in: International journal of oncology, Vol. 40, Issue 2, pp. 519-26, (2011) (PubMed).
: "Effect of catch-up growth after food restriction on the entero-insular axis in rats." in: Nutrition & metabolism, Vol. 7, pp. 45, (2010) (PubMed).
: "
-
Chronic oscillating glucose challenges disarrange innate immune homeostasis to potentiate the variation of neutrophil-lymphocyte ratio in rats with or without hidden diabetes mellitus." in: Diabetes, metabolic syndrome and obesity : targets and therapy, Vol. 11, pp. 277-288, (2018) (PubMed).
-
- Target
- Glucagon (GCG)
- Andere Bezeichnung
- GCG (GCG Produkte)
- Hintergrund
-
Synonyms: Glucagon,Glicentin,Glicentin-related polypeptide,GRPP,Oxyntomodulin,OXM,OXY,Glucagon,Glucagon-like peptide 1,GLP-1,Incretin hormone,Glucagon-like peptide 1 (7-37),GLP-1 (7-37),Glucagon-like peptide 1 (7-36),GLP-1 (7-36),Glucagon-like peptide 2,GLP-2,GCG,
Tissue Specificity: Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP-1 and GLP-2 are also secreted in selected neurons in the brain.
Background: GCG is also known as GLP1, or Glucagon. Glucagon is a 29-amino acid pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis.?It is mapped to 2q36-2q37. GLP1, also known as 7-37 for the codons of the preproglucagon molecule which encode it, renders pancreatic beta-cells 'glucose-competent' and may be useful in the treatment of noninsulin-dependent diabetes mellitus. Also, GLP1 is a potent insulin secretagogue.?It plays a major role in the enteroinsular axis, accounting, for example, for the finding that plasma insulin levels accompanying oral intake of glucose are greater than those observed when glucose is given intravenously.
- Molekulargewicht
- 10 kDa
- Gen-ID
- 2641
- UniProt
- P01275
- Pathways
- Positive Regulation of Peptide Hormone Secretion, Peptide Hormone Metabolism, cAMP Metabolic Process, Regulation of Carbohydrate Metabolic Process, Feeding Behaviour, Negative Regulation of intrinsic apoptotic Signaling
-